NASDAQ:EVOK - Evoke Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.05 0.00 (0.00 %)
(As of 05/22/2018 04:31 AM ET)
Previous Close$3.05
Today's Range$2.95 - $3.10
52-Week Range$1.85 - $4.09
Volume114,133 shs
Average Volume94,014 shs
Market Capitalization$51.16 million
P/E Ratio-3.67
Dividend YieldN/A
Beta1.35

About Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma logoEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.

Receive EVOK News and Ratings via Email

Sign-up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EVOK
CUSIPN/A
Phone858-345-1494

Debt

Debt-to-Equity RatioN/A
Current Ratio4.69
Quick Ratio4.69

Price-To-Earnings

Trailing P/E Ratio-3.67
Forward P/E Ratio30.50
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book21.79

Profitability

EPS (Most Recent Fiscal Year)($0.83)
Net Income$-12,220,000.00
Net MarginsN/A
Return on Equity-303.87%
Return on Assets-124.65%

Miscellaneous

Employees7
Outstanding Shares16,770,000

Evoke Pharma (NASDAQ:EVOK) Frequently Asked Questions

What is Evoke Pharma's stock symbol?

Evoke Pharma trades on the NASDAQ under the ticker symbol "EVOK."

How were Evoke Pharma's earnings last quarter?

Evoke Pharma (NASDAQ:EVOK) issued its earnings results on Wednesday, May, 16th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06. View Evoke Pharma's Earnings History.

What price target have analysts set for EVOK?

5 equities research analysts have issued 1 year price objectives for Evoke Pharma's stock. Their forecasts range from $5.00 to $10.00. On average, they expect Evoke Pharma's stock price to reach $8.80 in the next year. View Analyst Ratings for Evoke Pharma.

What are Wall Street analysts saying about Evoke Pharma stock?

Here are some recent quotes from research analysts about Evoke Pharma stock:
  • 1. According to Zacks Investment Research, "Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. " (5/21/2018)
  • 2. HC Wainwright analysts commented, "Ahead to Gimoti NDA Submission; Reiterate Buy Stock Data 03/08/2018 Price $2.08 Exchange NASDAQ Price Target $9.00 52-Week High $4.09 52-Week Low $1.85 Enterprise Value (M) $24.3 Market Cap (M) $32 Public Market Float (M) 12.1 Shares Outstanding (M) 15.4 3 Month Avg Volume 97,821 Short Interest (M) 1.19 Balance Sheet Metrics Cash (M) $7.7 Total Debt (M) $0.0 Total Cash/Share $0.50 Book Value/Share $0.13 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.45) (0.37) (0.14) 2Q (0.41) (0.11) (0.09) 3Q (0.29) (0.34) (0.07) 4Q (0.12) (0.02) (0.18) FY (1.15) (0.90) (0.47) 4.5 4 3.5 3 2.5 2 1.5 MAR- 17 J UL- 17 NOV- 17 MAR- 18 6 5 4 3 2 1 0 Vol. (mil) Price 2017 financial results reported. Earlier this week, Evoke Pharma reported its fourth quarter and full-year 2017 financial results. Its net loss of $0.02 per share was substantially better than our projection of a per-share net loss of $0.18." (3/6/2018)
  • 3. FBR & Co analysts commented, "Last week, we hosted EVOK’s management, including CEO David Gonyer RPh, along with chief business officer Matthew D’Onofrio, for a conference call with investors. Our call came after EVOK had reported positive results from a comparative PK study with its pipeline drug, Gimoti nasal spray, for treating symptoms of diabetic gastroparesis (delayed stomach emptying not caused by obstruction), versus Reglan. Bottom line: The results showed that two of three doses met targeted bioequivalence ranges, versus Reglan tablets; and EVOK plans to submit its 505 (b) (2) NDA with the FDA during 1Q18. This sets up a potential approval for EVOK’s drug by late 2018/early 2019; we have previously highlighted a peak potential of ~$500M for Gimoti and sales of ~$245M by 2022, with the scenario that EVOK self-markets, building its own sales force, and sees revenue and earnings ramps starting in 2019. Our price target of $10/share reflects a P/E multiple–based target, based upon 2022E earnings power, and a 13.5x multiple, discounted at 15%/year to present value, along with an additional 25% risk discount." (10/30/2017)

Who are some of Evoke Pharma's key competitors?

Who are Evoke Pharma's key executives?

Evoke Pharma's management team includes the folowing people:
  • Mr. Cam L. Garner, Co-Founder & Chairperson (Age 70)
  • Mr. David A. Gonyer R.Ph., Chief Exec. Officer, Pres & Director (Age 54)
  • Mr. Matthew J. D'Onofrio MBA, Co-Founder, Chief Bus. Officer, Exec. VP, Treasurer & Sec. (Age 48)
  • Dr. Marilyn R. Carlson D.M.D., M.D., RAC., Chief Medical Officer (Age 70)
  • Dr. Wayne Alves Ph.D., Sr. Director of Clinical Operations

Has Evoke Pharma been receiving favorable news coverage?

Media headlines about EVOK stock have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Evoke Pharma earned a media sentiment score of 0.09 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 46.60 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Evoke Pharma's major shareholders?

Evoke Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sphera Funds Management LTD. (2.54%). Company insiders that own Evoke Pharma stock include Kenneth J Widder and Parters Vii L P Domain. View Institutional Ownership Trends for Evoke Pharma.

Which major investors are selling Evoke Pharma stock?

EVOK stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD.. View Insider Buying and Selling for Evoke Pharma.

How do I buy shares of Evoke Pharma?

Shares of EVOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evoke Pharma's stock price today?

One share of EVOK stock can currently be purchased for approximately $3.05.

How big of a company is Evoke Pharma?

Evoke Pharma has a market capitalization of $51.16 million. The specialty pharmaceutical company earns $-12,220,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Evoke Pharma employs 7 workers across the globe.

How can I contact Evoke Pharma?

Evoke Pharma's mailing address is 420 STEVENS AVENUE SUITE 370, SOLANA BEACH CA, 92075. The specialty pharmaceutical company can be reached via phone at 858-345-1494 or via email at [email protected]


MarketBeat Community Rating for Evoke Pharma (EVOK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  155 (Vote Underperform)
Total Votes:  440
MarketBeat's community ratings are surveys of what our community members think about Evoke Pharma and other stocks. Vote "Outperform" if you believe EVOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVOK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Evoke Pharma (NASDAQ:EVOK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Evoke Pharma in the last 12 months. Their average twelve-month price target is $8.80, suggesting that the stock has a possible upside of 188.52%. The high price target for EVOK is $10.00 and the low price target for EVOK is $5.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.862.88
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.80$8.80$9.1429$9.00
Price Target Upside: 188.52% upside323.08% upside242.43% upside237.08% upside

Evoke Pharma (NASDAQ:EVOK) Consensus Price Target History

Price Target History for Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ:EVOK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018HC WainwrightSet Price TargetBuy$9.00LowView Rating Details
3/8/2018B. RileyReiterated RatingBuy ➝ Buy$10.00 ➝ $5.00MediumView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$10.00N/AView Rating Details
10/18/2017Northland SecuritiesReiterated RatingBuy$10.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$10.00N/AView Rating Details
3/16/2017Ascendiant Capital MarketsBoost Price TargetIn-Line$5.00 ➝ $6.00HighView Rating Details
3/16/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$6.00 ➝ $9.00HighView Rating Details
1/30/2017LaidlawUpgradeNeutral ➝ Buy$8.00N/AView Rating Details
8/16/2016Noble FinancialReiterated RatingHoldN/AView Rating Details
7/18/2016Feltl & Co.DowngradeStrong-Buy ➝ SellN/AView Rating Details
7/18/2016Brean CapitalDowngradeBuy ➝ HoldN/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Evoke Pharma (NASDAQ:EVOK) Earnings History and Estimates Chart

Earnings by Quarter for Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ:EVOK) Earnings Estimates

2018 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.14)($0.14)($0.14)
Q3 20181($0.06)($0.06)($0.06)
Q4 20181($0.06)($0.06)($0.06)

Evoke Pharma (NASDAQ EVOK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/2018Q1 2018($0.19)($0.13)ViewN/AView Earnings Details
3/7/2018Q4 2017($0.23)($0.02)ViewListenView Earnings Details
11/14/2017Q3 2017($0.21)($0.34)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.12)($0.27)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.16)($0.14)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.19)($0.12)ViewN/AView Earnings Details
11/9/2016Q316($0.27)($0.29)ViewListenView Earnings Details
8/15/2016Q216($0.43)($0.41)ViewListenView Earnings Details
5/11/2016Q116($0.41)($0.45)ViewListenView Earnings Details
3/10/2016Q415($0.45)($0.37)ViewListenView Earnings Details
11/12/2015Q315($0.56)($0.42)ViewListenView Earnings Details
8/13/2015Q215($0.60)($0.52)ViewListenView Earnings Details
5/14/2015Q115($0.55)($0.58)ViewListenView Earnings Details
3/4/2015Q414($0.80)($0.48)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.78)($0.63)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.73)($0.59)ViewN/AView Earnings Details
5/13/2014Q114($0.38)($0.49)ViewN/AView Earnings Details
3/25/2014Q413($0.16)($0.27)ViewN/AView Earnings Details
11/13/2013Q3 13($0.10)($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Evoke Pharma (NASDAQ:EVOK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Evoke Pharma (NASDAQ EVOK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.94%
Institutional Ownership Percentage: 13.64%
Insider Trading History for Evoke Pharma (NASDAQ:EVOK)
Institutional Ownership by Quarter for Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma (NASDAQ EVOK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2017Kenneth J WidderDirectorBuy450,000$2.90$1,305,000.00View SEC Filing  
5/26/2016Parters Vii L P DomainMajor ShareholderSell344,120$4.70$1,617,364.00View SEC Filing  
4/27/2016Parters Vii L P DomainMajor ShareholderSell5,095$5.07$25,831.65View SEC Filing  
4/25/2016Parters Vii L P DomainMajor ShareholderSell1,492$5.20$7,758.40View SEC Filing  
4/20/2016Parters Vii L P DomainMajor ShareholderSell41,478$5.35$221,907.30View SEC Filing  
4/11/2016Parters Vii L P DomainMajor ShareholderSell4,348$5.22$22,696.56View SEC Filing  
4/8/2016Parters Vii L P DomainMajor ShareholderSell51,004$5.28$269,301.12View SEC Filing  
8/18/2015Parters Vii L P DomainMajor ShareholderSell11,836$7.02$83,088.72View SEC Filing  
4/16/2015Parters Vii L P DomainMajor ShareholderSell50,163$7.29$365,688.27View SEC Filing  
9/23/2014Todd C BradyDirectorBuy4,000$5.70$22,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Evoke Pharma (NASDAQ EVOK) News Headlines

Source:
DateHeadline
B. Riley Brokers Boost Earnings Estimates for Evoke Pharma (EVOK)B. Riley Brokers Boost Earnings Estimates for Evoke Pharma (EVOK)
www.americanbankingnews.com - May 18 at 7:58 AM
Evoke Pharma (EVOK) Announces Quarterly  Earnings ResultsEvoke Pharma (EVOK) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 15 at 8:28 AM
Evoke Pharma Inc (NASDAQ:EVOK) Is Expected To BreakevenEvoke Pharma Inc (NASDAQ:EVOK) Is Expected To Breakeven
finance.yahoo.com - May 14 at 5:01 PM
BRIEF-Evoke Pharma Posts Loss Of $0.13 Per Share in Q1BRIEF-Evoke Pharma Posts Loss Of $0.13 Per Share in Q1
www.reuters.com - May 14 at 9:09 AM
Evoke net loss improves in Q1Evoke net loss improves in Q1
seekingalpha.com - May 14 at 9:09 AM
Evoke Pharma Reports First Quarter 2018 Results and HighlightsEvoke Pharma Reports First Quarter 2018 Results and Highlights
finance.yahoo.com - May 14 at 9:09 AM
Evoke Pharma (EVOK) Expected to Announce Earnings of -$0.17 Per ShareEvoke Pharma (EVOK) Expected to Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 10 at 7:19 PM
Evoke Granted Gender Specific Patent for Gimoti™ in MexicoEvoke Granted Gender Specific Patent for Gimoti™ in Mexico
finance.yahoo.com - May 10 at 8:55 AM
Evoke Pharma (EVOK) Upgraded to "Buy" at Zacks Investment ResearchEvoke Pharma (EVOK) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 8 at 11:57 PM
Evoke Pharma (EVOK) Scheduled to Post Quarterly Earnings on MondayEvoke Pharma (EVOK) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 2:50 AM
Evoke Pharma (EVOK) Rating Increased to Sell at ValuEngineEvoke Pharma (EVOK) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - May 4 at 12:13 AM
HC Wainwright Reiterates "$9.00" Price Target for Evoke Pharma (EVOK)HC Wainwright Reiterates "$9.00" Price Target for Evoke Pharma (EVOK)
www.americanbankingnews.com - May 3 at 12:52 PM
Evoke Granted First Gender Specific Patent for Gimoti™Evoke Granted First Gender Specific Patent for Gimoti™
finance.yahoo.com - April 30 at 8:53 AM
Evoke Pharma (EVOK) Receives Average Recommendation of "Buy" from BrokeragesEvoke Pharma (EVOK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 29 at 7:36 PM
-$0.17 Earnings Per Share Expected for Evoke Pharma (EVOK) This Quarter-$0.17 Earnings Per Share Expected for Evoke Pharma (EVOK) This Quarter
www.americanbankingnews.com - April 23 at 11:20 AM
 Brokerages Expect Evoke Pharma Inc (EVOK) to Announce -$0.17 EPS Brokerages Expect Evoke Pharma Inc (EVOK) to Announce -$0.17 EPS
www.americanbankingnews.com - April 6 at 11:29 AM
Evoke Pharmas (EVOK) "Buy" Rating Reiterated at HC WainwrightEvoke Pharma's (EVOK) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 5 at 7:26 PM
Evoke Pharma Inc (EVOK) Receives Average Rating of "Buy" from AnalystsEvoke Pharma Inc (EVOK) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 4 at 7:28 PM
Evoke Pharma (EVOK) Given Buy Rating at HC WainwrightEvoke Pharma (EVOK) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - April 2 at 8:03 AM
CMO Today: FTC Probes Facebook; Meredith Reshuffles Ad Team; Apple News Steps Up MonetizationCMO Today: FTC Probes Facebook; Meredith Reshuffles Ad Team; Apple News Steps Up Monetization
www.wsj.com - March 27 at 4:52 PM
Evoke extends cash runway with agreement with Mallinckrodt to defer Gimoti milestonesEvoke extends cash runway with agreement with Mallinckrodt to defer Gimoti milestones
seekingalpha.com - March 26 at 4:51 PM
Zacks: Analysts Expect Evoke Pharma Inc (EVOK) to Announce -$0.17 EPSZacks: Analysts Expect Evoke Pharma Inc (EVOK) to Announce -$0.17 EPS
www.americanbankingnews.com - March 20 at 11:25 AM
Evoke Pharma Inc (EVOK) to Post Q1 2018 Earnings of ($0.19) Per Share, B. Riley ForecastsEvoke Pharma Inc (EVOK) to Post Q1 2018 Earnings of ($0.19) Per Share, B. Riley Forecasts
www.americanbankingnews.com - March 12 at 2:32 AM
Evoke Pharma Inc (EVOK) Receives Consensus Recommendation of "Buy" from AnalystsEvoke Pharma Inc (EVOK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 10 at 7:30 PM
Evoke Pharma (EVOK) Stock Rating Lowered by Zacks Investment ResearchEvoke Pharma (EVOK) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 9 at 10:14 PM
Brokers Offer Predictions for Evoke Pharma Incs FY2022 Earnings (EVOK)Brokers Offer Predictions for Evoke Pharma Inc's FY2022 Earnings (EVOK)
www.americanbankingnews.com - March 9 at 4:32 PM
Evoke Pharma (EVOK) Price Target Cut to $5.00Evoke Pharma (EVOK) Price Target Cut to $5.00
www.americanbankingnews.com - March 8 at 11:04 PM
Evoke Pharma (EVOK) Lifted to Buy at Zacks Investment ResearchEvoke Pharma (EVOK) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 8 at 9:58 PM
Evoke Pharma (EVOK) Releases Quarterly  Earnings Results, Beats Expectations By $0.21 EPSEvoke Pharma (EVOK) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS
www.americanbankingnews.com - March 8 at 10:56 AM
Evoke Pharmas (EVOK) CEO Dave Gonyer on Q4 2017 Results - Earnings Call TranscriptEvoke Pharma's (EVOK) CEO Dave Gonyer on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 8 at 8:57 AM
Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent HighlightsEvoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 7 at 5:57 PM
Evoke Pharma (EVOK) Receives Buy Rating from HC WainwrightEvoke Pharma (EVOK) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - March 6 at 1:16 PM
Evoke Pharma (EVOK) Announces FDA Approves PDUFA Fee Waiver for Gimoti NDAEvoke Pharma (EVOK) Announces FDA Approves PDUFA Fee Waiver for Gimoti NDA
www.streetinsider.com - March 6 at 8:44 AM
Evoke Pharma (EVOK) to Release Quarterly Earnings on TuesdayEvoke Pharma (EVOK) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM
FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug ApplicationFDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application
finance.yahoo.com - March 5 at 8:48 AM
Evoke Pharma Inc (EVOK) Expected to Post Earnings of -$0.22 Per ShareEvoke Pharma Inc (EVOK) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - March 3 at 3:44 PM
Contrasting Akorn (AKRX) & Evoke Pharma (EVOK)Contrasting Akorn (AKRX) & Evoke Pharma (EVOK)
www.americanbankingnews.com - February 22 at 3:48 PM
Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial ResultsEvoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - February 21 at 8:50 AM
EVOKE PHARMA, INC. - StreetInsider.comEVOKE PHARMA, INC. - StreetInsider.com
www.streetinsider.com - February 15 at 8:13 AM
Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™
finance.yahoo.com - February 15 at 8:13 AM
Evoke Pharma Inc (EVOK) Expected to Announce Earnings of -$0.22 Per ShareEvoke Pharma Inc (EVOK) Expected to Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - February 14 at 3:10 PM
Evoke Pharma Inc (EVOK) Given Average Recommendation of "Buy" by AnalystsEvoke Pharma Inc (EVOK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 13 at 7:30 PM
Evoke Pharma (EVOK) Raised to Hold at Zacks Investment ResearchEvoke Pharma (EVOK) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - February 6 at 11:06 PM
Evoke Pharma (EVOK) Upgraded to "Hold" by Zacks Investment ResearchEvoke Pharma (EVOK) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 31 at 11:58 PM
Zacks: Analysts Expect Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.22 Per ShareZacks: Analysts Expect Evoke Pharma Inc (EVOK) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - January 28 at 5:12 PM
 Analysts Anticipate Evoke Pharma Inc (EVOK) to Announce -$0.22 EPS Analysts Anticipate Evoke Pharma Inc (EVOK) to Announce -$0.22 EPS
www.americanbankingnews.com - December 26 at 5:46 AM
Evoke Pharma Inc (EVOK) Given Consensus Recommendation of "Buy" by AnalystsEvoke Pharma Inc (EVOK) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 25 at 7:54 PM
Head to Head Review: Sagent Pharmaceuticals (SGNT) and Evoke Pharma (EVOK)Head to Head Review: Sagent Pharmaceuticals (SGNT) and Evoke Pharma (EVOK)
www.americanbankingnews.com - December 15 at 11:16 PM
Wired News – Akari’s Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary EndpointWired News – Akari’s Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint
finance.yahoo.com - December 12 at 10:05 AM
Wired News – SteadyMed Reported FDA Agreed Pathway to Trevyent NDA ResubmissionWired News – SteadyMed Reported FDA Agreed Pathway to Trevyent NDA Resubmission
finance.yahoo.com - December 11 at 10:24 AM

SEC Filings

Evoke Pharma (NASDAQ:EVOK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Evoke Pharma (NASDAQ:EVOK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Evoke Pharma (NASDAQ EVOK) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.